Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. Sep-Oct 2009;54(5):33-7.

[Vitaherpavac Is the First Russian Herpes Simplex Virus Vaccine Obtained on the Vero B Continuous Cell Line]

[Article in Russian]
  • PMID: 19882901
Clinical Trial

[Vitaherpavac Is the First Russian Herpes Simplex Virus Vaccine Obtained on the Vero B Continuous Cell Line]

[Article in Russian]
O A Barkhaleva et al. Vopr Virusol. .

Abstract

Vitaherpavac, a dry inactivated herpes simplex virus (HSV) culture vaccine, has been obtained, by using the Vero B continuous cell line as a substrate for accumulation of herpes simplex virus types 1 (US strain) and 2 (VN strain). Vitaherpavac and the similar vaccine Herpovax made by the Research Institute of Vaccines and Sera, Saint Petersburg (for which preparation a primary trypsinized chick embryo cell culture used as a substrate for accumulation of HSV types 1 and 2), underwent comparative clinical trials. The tolerability and therapeutic effectiveness of the vaccine were tested in patients diagnosed as having chronic frequently recurring herpes. The trials have yielded positive results that suggest that it is expedient to introduce of the new vaccine Vitaherpavac into practice to treat chronic recurrent herpetic infection of various localizations. Vitaherpavac has been registered in the Russian Federation and permitted for medical application.

Similar articles

See all similar articles

Publication types

MeSH terms

LinkOut - more resources

Feedback